Shenyang Pharma Univ. ROCK2 compound S9

Shenyang Pharma Univ. ROCK2 compound S9: sourced facts only. name: "Kinase-Glo assay identified cyclopentylamino analogues S9 (ROCK2 IC50 = 0.020 μM) as the most potent ROCK2 inhibitor with 41-fold selectivity over isoform ROCK1 (ROCK1 IC50 = 0.821 μM)." [PMID:40811902]; target: "Kinase-Glo assay identified cyclopentylamino analogues S9 (ROCK2 IC50 = 0.020 μM) as the most potent ROCK2 inhibitor with 41-fold selectivity over isoform ROCK1 (ROCK1 IC50 = 0.821 μM)." [PMID:40811902]; developer: "Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China." [PMID:40811902]; stage: "Immunofluorescence imaging illustrated that S9 (5 μM) could disrupt the cytoskeletal organization of MDA-MB-231 cells, and the superior inhibitory potency of S9 against cancer cell metastasis in vitro was further verified with cell scratch assay." [PMID:40811902]